Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Micreos Human Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Micreos Initiates Clinical Trial to Evaluate World\u2019s First Endolysin-Drug as a Therapy for Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Micreos Human Health"},{"company":"Micreos Human Health","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$37.1 million","upfrontCash":"Undisclosed","newsHeadline":"Micreos Secures \u20ac32 Million for Its Endolysin-Based Platform as Sustainable Alternative to Antibiotics","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Micreos Human Health"}]

Micreos Human Health

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Micreos Secures €32 Million for Its Endolysin-Based Platform as Sustainable Alternative to Antibiotics

Details:

This funding round will help Micreos accelerate its clinical development programs for atopic dermatitis, diabetic (MRSA) wounds and bloodstream infections, based on its pharmaceutical lead compounds, XZ.700 and SP.800.

Lead Product(s): XZ.700

Therapeutic Area: Dermatology Product Name: XZ.700

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $37.1 million Upfront Cash: Undisclosed

Deal Type: Funding September 30, 2021

ASK
US

Upload
your Pipeline Activity

Micreos Human Health

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Micreos Initiates Clinical Trial to Evaluate World’s First Endolysin-Drug as a Therapy for Atopic Dermatitis

Details:

Micreos Human Health has enrolled the first patients in a Phase I/IIa, randomized, double-blind, placebo-controlled, parallel treated dose-ranging study to assess the safety and efficacy of XZ.700 in patients with mild to moderate atopic dermatitis.

Lead Product(s): XZ.700

Therapeutic Area: Dermatology Product Name: XZ.700

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 22, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY